Literature DB >> 19528441

Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma.

Joseph Schwab1, Cristina Antonescu, Patrick Boland, John Healey, Andrew Rosenberg, Petur Nielsen, John Iafrate, Thomas Delaney, Sam Yoon, Edwin Choy, David Harmon, Kevin Raskin, Cao Yang, Henry Mankin, Dempsey Springfield, Francis Hornicek, Zhenfeng Duan.   

Abstract

BACKGROUND: Chordomas are rare tumors of the axial skeleton for which surgical resection remains the most reliable means of cure. PI-103 is a inhibitor of PI3K/AKT and mTOR activation. This study aims to determine whether the PI3K/mTOR pathway was active in chordomas and whether their inhibition could lead to decreased proliferation and increased apoptosis.
MATERIALS AND METHODS: Thirteen human chordoma were tested for activation of the PI3K/mTOR pathway. The human chordoma cell line UCH-1 was treated with increasing doses of PI-103. Inhibition of AKT and mTOR was examined and assays assessing proliferation and apoptosis were performed.
RESULTS: The chordoma specimen demonstrated activation of the PI3K/mTOR pathway. PI-103 inhibited the AKT and mTOR activation in the UCH-1 cell line. PI-103 inhibited proliferation and induced apoptosis in UCH-1.
CONCLUSION: The PI3K/AKT and mTOR signaling pathway is constitutively activated in chordoma. PI-103 decreases proliferation and induces apoptosis in the UCH-1 via inhibition of the PI3K/mTOR pathway.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19528441

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  27 in total

1.  Chordoma: an update on the pathophysiology and molecular mechanisms.

Authors:  Xin Sun; Francis Hornicek; Joseph H Schwab
Journal:  Curr Rev Musculoskelet Med       Date:  2015-12

Review 2.  Current therapeutic options and novel molecular markers in skull base chordomas.

Authors:  Filippo Gagliardi; Nicola Boari; Paola Riva; Pietro Mortini
Journal:  Neurosurg Rev       Date:  2011-10-18       Impact factor: 3.042

Review 3.  The notochord: structure and functions.

Authors:  Diana Corallo; Valeria Trapani; Paolo Bonaldo
Journal:  Cell Mol Life Sci       Date:  2015-04-02       Impact factor: 9.261

4.  mTORC1 inhibition and ECM-cell adhesion-independent drug resistance via PI3K-AKT and PI3K-RAS-MAPK feedback loops.

Authors:  Karina Galoian; H T Temple; Armen Galoyan
Journal:  Tumour Biol       Date:  2012-01-14

5.  Inhibition of PI3K/Akt/mTOR signaling pathway enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin in vitro.

Authors:  Yunlang Cai; Xiaoqiang Tan; Jun Liu; Yang Shen; Di Wu; Mulan Ren; Peilin Huang; Dandan Yu
Journal:  Chin J Cancer Res       Date:  2014-10       Impact factor: 5.087

Review 6.  Systemic therapy options for unresectable and metastatic chordomas.

Authors:  Silvia Stacchiotti; Paolo Giovanni Casali
Journal:  Curr Oncol Rep       Date:  2011-08       Impact factor: 5.075

Review 7.  The biological basis for modern treatment of chordoma.

Authors:  Roberto Jose Diaz; Michael D Cusimano
Journal:  J Neurooncol       Date:  2011-03-08       Impact factor: 4.130

8.  Multidisciplinary management of recurrent chordomas.

Authors:  Yoshiya Yamada; Mrinal Gounder; Ilya Laufer
Journal:  Curr Treat Options Oncol       Date:  2013-09

Review 9.  The molecular aspects of chordoma.

Authors:  Sukru Gulluoglu; Ozlem Turksoy; Aysegul Kuskucu; Ugur Ture; Omer Faruk Bayrak
Journal:  Neurosurg Rev       Date:  2015-09-12       Impact factor: 3.042

10.  Chemotherapy of skull base chordoma tailored on responsiveness of patient-derived tumor cells to rapamycin.

Authors:  Lucia Ricci-Vitiani; Daniele Runci; Quintino Giorgio D'Alessandris; Tonia Cenci; Maurizio Martini; Federico Bianchi; Giulio Maira; Louis Stancato; Ruggero De Maria; Luigi Maria Larocca; Roberto Pallini
Journal:  Neoplasia       Date:  2013-07       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.